PE20010299A1 - DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5 - Google Patents

DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5

Info

Publication number
PE20010299A1
PE20010299A1 PE2000000672A PE0006722000A PE20010299A1 PE 20010299 A1 PE20010299 A1 PE 20010299A1 PE 2000000672 A PE2000000672 A PE 2000000672A PE 0006722000 A PE0006722000 A PE 0006722000A PE 20010299 A1 PE20010299 A1 PE 20010299A1
Authority
PE
Peru
Prior art keywords
decahydroisoquinoline
methyl
carboxyl
acid
derivatives
Prior art date
Application number
PE2000000672A
Other languages
English (en)
Spanish (es)
Inventor
David Bleakman
Amy Suzon Chappell
Paul Leslie Ornstein
Kirk Willis Johnson
Sandra Ann Filla
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010299A1 publication Critical patent/PE20010299A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2000000672A 1999-07-06 2000-07-04 DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5 PE20010299A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
PE20010299A1 true PE20010299A1 (es) 2001-03-07

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000672A PE20010299A1 (es) 1999-07-06 2000-07-04 DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5

Country Status (28)

Country Link
US (4) US6566370B1 (https=)
EP (1) EP1200073B1 (https=)
JP (1) JP4619595B2 (https=)
KR (1) KR20020024300A (https=)
CN (1) CN1230174C (https=)
AR (1) AR029373A1 (https=)
AU (1) AU773304B2 (https=)
BR (1) BR0012175A (https=)
CA (1) CA2378613C (https=)
CZ (1) CZ20014488A3 (https=)
DE (1) DE60032905T2 (https=)
DK (1) DK1200073T3 (https=)
DZ (1) DZ3209A1 (https=)
EA (1) EA004290B1 (https=)
ES (1) ES2278619T3 (https=)
HK (1) HK1047036A1 (https=)
HR (1) HRP20020013A2 (https=)
HU (1) HUP0202253A3 (https=)
IL (1) IL146697A0 (https=)
MX (1) MXPA01012726A (https=)
MY (1) MY133503A (https=)
NO (1) NO20016246L (https=)
NZ (1) NZ515616A (https=)
PE (1) PE20010299A1 (https=)
PT (1) PT1200073E (https=)
SK (1) SK112002A3 (https=)
TR (1) TR200200066T2 (https=)
WO (1) WO2001001972A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2002227020A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
EA200300770A1 (ru) * 2001-01-05 2003-10-30 Эли Лилли Энд Компани Антагонисты рецепторов возбуждающей аминокислоты
AU2002228736A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
EP1511741B1 (en) 2002-04-26 2012-12-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
SG174095A1 (en) 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US10591492B2 (en) 2018-03-05 2020-03-17 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
EA199900912A1 (ru) * 1997-04-07 2000-04-24 Эли Лилли Энд Компани Фармацевтические средства
ATE240299T1 (de) * 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure

Also Published As

Publication number Publication date
NO20016246L (no) 2002-03-04
WO2001001972A2 (en) 2001-01-11
KR20020024300A (ko) 2002-03-29
EP1200073B1 (en) 2007-01-10
HUP0202253A2 (hu) 2002-11-28
US7157582B2 (en) 2007-01-02
EA004290B1 (ru) 2004-02-26
IL146697A0 (en) 2002-07-25
NO20016246D0 (no) 2001-12-19
CA2378613C (en) 2007-10-02
US6855823B2 (en) 2005-02-15
WO2001001972A3 (en) 2001-12-06
ES2278619T3 (es) 2007-08-16
CN1359289A (zh) 2002-07-17
PT1200073E (pt) 2007-03-30
MXPA01012726A (es) 2002-07-02
JP4619595B2 (ja) 2011-01-26
AR029373A1 (es) 2003-06-25
US6759418B2 (en) 2004-07-06
EA200200132A1 (ru) 2002-06-27
DK1200073T3 (da) 2007-05-07
EP1200073A2 (en) 2002-05-02
DZ3209A1 (fr) 2001-01-11
HK1047036A1 (zh) 2003-02-07
AU5873200A (en) 2001-01-22
BR0012175A (pt) 2002-03-05
DE60032905T2 (de) 2007-10-18
US20030199546A1 (en) 2003-10-23
CN1230174C (zh) 2005-12-07
CA2378613A1 (en) 2001-01-11
HUP0202253A3 (en) 2003-12-29
SK112002A3 (en) 2003-05-02
DE60032905D1 (de) 2007-02-22
US20050159445A1 (en) 2005-07-21
TR200200066T2 (tr) 2002-04-22
US6566370B1 (en) 2003-05-20
MY133503A (en) 2007-11-30
NZ515616A (en) 2004-05-28
US20040192722A1 (en) 2004-09-30
AU773304B2 (en) 2004-05-20
CZ20014488A3 (cs) 2003-01-15
JP2003503449A (ja) 2003-01-28
HRP20020013A2 (en) 2003-08-31

Similar Documents

Publication Publication Date Title
PE20010299A1 (es) DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5
IS6362A (is) Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
EA199800604A1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперидинина как антагонисты рецепторов тахикинина
DK1177176T3 (da) Triarylsyrederivater som PPAR-receptorligander
DE69006131D1 (de) Substituierte Chinazolinone als Angiotensin II-Antagonisten.
AR022230A1 (es) Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
PE20011029A1 (es) Compuestos de dihidropirimidina heterociclicos como inhibidores del canal de potasio
DE69530690D1 (de) Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren
ATE297203T1 (de) Antithrombotische mitteln
AR029417A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
SE9904508D0 (sv) New compounds
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
EA200401167A1 (ru) Производные тропана в качестве модуляторов ccr5
ATE340795T1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
ES2168383T3 (es) Derivados de 1,2,3,4-tetrahidroquinoxalindiona y su utilizacion como antagonistas del glutamato receptor.
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20021013A1 (es) Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos
DK1157998T3 (da) Heterocykliske forbindelser, mellemprodukter derfor og elastaseinhibitorer
AR018877A1 (es) Un procedimiento para la preparacion de derivados de morfolina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed